Literature DB >> 11587793

Staphylococcal resistance to antimicrobial peptides of mammalian and bacterial origin.

A Peschel1, L V Collins.   

Abstract

Antimicrobial host defense peptides, such as defensins, protegrins, and platelet microbicidal proteins are deployed by mammalian skin, epithelia, phagocytes, and platelets in response to Staphylococcus aureus infection. In addition, staphylococcal products with similar structures and activities, called bacteriocins, inhibit competing microorganisms. Staphylococci have developed resistance mechanisms, which are either highly specific for certain host defense peptides or bacteriocins or which broadly protect against a range of cationic antimicrobial peptides. Experimental infection models can be used to study the molecular mechanisms of antimicrobial peptides, the peptide resistance strategies of S. aureus, and the therapeutic potential of peptides in staphylococcal diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11587793     DOI: 10.1016/s0196-9781(01)00500-9

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  34 in total

1.  The msaABCR operon regulates resistance in vancomycin-intermediate Staphylococcus aureus strains.

Authors:  Dhritiman Samanta; Mohamed O Elasri
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

2.  Structure-function characterization and optimization of a plant-derived antibacterial peptide.

Authors:  Mougli Suarez; Marisa Haenni; Stéphane Canarelli; Florian Fisch; Pierre Chodanowski; Catherine Servis; Olivier Michielin; Ruth Freitag; Philippe Moreillon; Nicolas Mermod
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

3.  Cyclooxygenase-2 enhances antimicrobial peptide expression and killing of Staphylococcus aureus.

Authors:  Jamie J Bernard; Richard L Gallo
Journal:  J Immunol       Date:  2010-10-22       Impact factor: 5.422

4.  Experimental evolution of resistance to an antimicrobial peptide.

Authors:  Gabriel G Perron; Michael Zasloff; Graham Bell
Journal:  Proc Biol Sci       Date:  2006-01-22       Impact factor: 5.349

5.  Inactivation of the antifungal and immunomodulatory properties of human cathelicidin LL-37 by aspartic proteases produced by the pathogenic yeast Candida albicans.

Authors:  Maria Rapala-Kozik; Oliwia Bochenska; Marcin Zawrotniak; Natalia Wolak; Grzegorz Trebacz; Mariusz Gogol; Dominika Ostrowska; Wataru Aoki; Mitsuyoshi Ueda; Andrzej Kozik
Journal:  Infect Immun       Date:  2015-04-06       Impact factor: 3.441

6.  Proteolytic degradation of human antimicrobial peptide LL-37 by Bacillus anthracis may contribute to virulence.

Authors:  Joanne E Thwaite; Stephen Hibbs; Richard W Titball; Timothy P Atkins
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

7.  Platelets and Platelet Inhibitors in Infective Endocarditis.

Authors:  Bruno Hoen
Journal:  Curr Infect Dis Rep       Date:  2002-08       Impact factor: 3.725

8.  Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains.

Authors:  Soo-Jin Yang; Yan Q Xiong; Paul M Dunman; Jacques Schrenzel; Patrice François; Andreas Peschel; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

9.  Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus.

Authors:  George Sakoulas; Cheryl Y Okumura; Wdee Thienphrapa; Joshua Olson; Poochit Nonejuie; Quang Dam; Abhay Dhand; Joseph Pogliano; Michael R Yeaman; Mary E Hensler; Arnold S Bayer; Victor Nizet
Journal:  J Mol Med (Berl)       Date:  2013-12-03       Impact factor: 4.599

10.  Immunity to the bacteriocin sublancin 168 Is determined by the SunI (YolF) protein of Bacillus subtilis.

Authors:  Jean-Yves F Dubois; Thijs R H M Kouwen; Anna K C Schurich; Carlos R Reis; Hendrik T Ensing; Erik N Trip; Jessica C Zweers; Jan Maarten van Dijl
Journal:  Antimicrob Agents Chemother       Date:  2008-12-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.